Close
4,839 Chinese medicine practitioners
0.5% identified as Aboriginal and/or Torres Strait Islander
57.8% female; 42.2% male
45 notifications lodged with Ahpra about
40 Chinese medicine practitioners
6 immediate actions taken
2 mandatory notifications received
19 practitioners monitored for health, performance and/or conduct
763 cases being monitored at 30 June:
11 criminal offence complaints made
11 closed
No matters decided by a tribunal
No matters decided by a panel
No appeals lodged
This year the Chinese Medicine Board of Australia celebrated 10 years of national regulation of Chinese medicine in Australia. This anniversary provided a valuable opportunity to reflect on how important this development was for the profession, with Chinese medicine practitioners now part of a national registration system that works to ensure the Australian community have trust and confidence that registered health practitioners are competent, safe and qualified to practise.
The Board continued to work with local jurisdictions to keep practitioners up to date with how local public health orders affected the profession. In August the Board joined co-regulators and the Therapeutic Goods Administration in publishing advice to the public on evidence-based information for COVID-19. In December the Board joined other National Boards providing guidance for practitioners on facilitating access to care in a COVID-19 environment.
The Board released a revised Code of conduct in partnership with several other Boards.
In November the Board kicked off the first of the new regulatory examinations with multiple-choice examinations. These examinations were held again in March. The second half of the regulatory examination, the objective structured clinical examination (OSCE), will be piloted soon, with the first session to occur by the end of 2022.
The Board conducted public consultation on proposed revisions to two guidelines, Guidelines on safe Chinese herbal medicine practice and Guidelines on infection prevention and control for acupuncture and related practices. The Board received much valuable feedback from these consultations, and we thank the participants for taking the time to assist the Board. The annual review of the Board’s Nomenclature compendium was also conducted.
In September the Board met with representatives of all professional organisations; as part of this meeting, members heard a fascinating presentation on the National Scheme’s commitment to cultural safety and the elimination of racism in healthcare. In December the Board held a practitioner webinar and provided an update to practitioners on policy issues in Chinese medicine and emerging trends from notifications, and presented a case study that illustrated the notification process.
The Board reviewed and renewed its Reference Group membership this year, with a new membership to include representatives from the insurance industry as well as all education providers.
The Board was pleased to be able to meet face to face with the Chinese Medicine Council of New South Wales. The joint meeting was a great opportunity for the Board and the Council to exchange experiences and views.
We were delighted to learn that Ms Bing Tian was re-appointed in October for a second term on the Board. This year the Board has been focused on reviewing membership and recruiting to the various Board committees, and we appointed new members Dr Yun Shen PhD and Ms Christina Lam to the Board’s Policy, Planning and Communications Committee (PPPCC) and the Board’s Registration, Notifications and Compliance Committee respectively. In June we bade farewell to a long-standing member of the PPPCC, Ms Glenys Savage, whose contribution to the committee was highly valued.
Adjunct Professor Danforn Lim